GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Clinical trials for GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets stomach and pancreatic cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a new drug called ASP2138, which helps the immune system attack cancer cells that have a specific marker (CLDN18.2). It is for people with advanced stomach, gastroesophageal junction (GEJ), or pancreatic cancer that cannot be removed by surgery or has…
Matched conditions: GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New pill targets hard-to-treat cancers with specific gene flaw
Disease control Recruiting nowThis study tests a new experimental drug called PLX-61639 for people with advanced solid tumors that have a specific genetic change (SMARCA4 mutation) and have stopped responding to standard treatments. The drug is taken as a daily pill and aims to shrink or control the cancer. A…
Matched conditions: GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Plexium, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC